# Tesamorelin FAQ: Common Questions About the GHRH Analogue, Answered and Cited > Tesamorelin FAQ: what it is, what it does, how it works, FDA status, half-life, IGF-1, visceral and liver fat, side effects, and non-HIV use — 22 direct, cited answers from the research literature. Twenty-two of the most common questions about tesamorelin, answered directly from the published research and cited to source. ## What is tesamorelin? Tesamorelin is a synthetic, stabilized analogue of the full-length human growth hormone-releasing hormone, GHRH(1-44), carrying a trans-3-hexenoyl group on its N-terminus that resists DPP-IV breakdown [8]. It is FDA-approved (2010) only to reduce excess abdominal visceral fat in HIV-associated lipodystrophy; every other use is off-label [5]. ## What does tesamorelin do? It prompts the pituitary to release the body's own growth hormone in natural pulses, which raises IGF-1 and promotes breakdown of visceral fat [4]. In the pivotal HIV trial, 2 mg/day cut visceral fat by 15.2% and raised IGF-1 by 81% over 26 weeks [1]. ## How does tesamorelin work? It binds the GHRH receptor on pituitary somatotroph cells, activating the cAMP/PKA pathway to trigger pulsatile growth-hormone release [4]. GH then drives hepatic IGF-1 production, and GH and IGF-1 together promote lipolysis in visceral fat [6] — amplifying the body's own rhythm rather than supplying external GH. ## Is tesamorelin FDA approved? Yes, but narrowly: it was approved in the United States in 2010 (NDA 022505) only to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [5]. Every other use — general or cosmetic fat loss, anti-aging, performance — is off-label and outside that approved indication [14]. ## Is tesamorelin like other weight-loss injections? No. Tesamorelin is a GHRH analogue that works through the growth-hormone axis to reduce visceral fat [4]. It belongs to a different drug class than GLP-1 receptor agonists and was studied for a different indication — HIV-associated lipodystrophy [1], not general weight loss. ## Is tesamorelin a peptide? Yes. It is a 44-amino-acid peptide — a synthetic analogue of GHRH(1-44) — with a trans-3-hexenoic acid group on its N-terminus [8]. It is not a steroid and not a GLP-1 receptor agonist; it is a peptide hormone analogue. ## Will tesamorelin help me lose belly fat? In HIV patients with abdominal fat accumulation, 2 mg/day selectively reduced visceral fat — 15.2% in the pivotal trial [1] and -27.71 cm2 in a 2026 meta-analysis [13] — generally without significant change in subcutaneous fat or BMI. Trials were conducted in HIV-positive adults; large non-HIV fat-loss RCTs have not been completed [14]. ## How long does it take to see fat loss from tesamorelin? Pivotal trials measured the primary visceral-fat endpoint at 26 weeks [1], with the effect sustained through 52 weeks of continued dosing [2]. Visceral fat reaccumulated within weeks of discontinuation, so the studied benefit depended on continued treatment [2]. ## Does tesamorelin burn belly fat? In the studied HIV population it preferentially reduced visceral adipose tissue via GH/IGF-1-driven lipolysis [6]. A 2026 meta-analysis of five RCTs reported visceral fat -27.71 cm2, trunk fat -1.18 kg, and hepatic fat -4.28%, with lean mass increasing slightly [13]. ## Is tesamorelin a growth hormone? No. Tesamorelin is not growth hormone; it is a GHRH analogue that prompts the pituitary to secrete the body's own GH in natural pulses [4]. In healthy men, 2 mg/day raised mean overnight GH by 0.5 ug/L and increased IGF-1 by 181 ug/L [4]. ## Does tesamorelin increase the risk of diabetes or affect blood sugar? GH-axis stimulation can modestly perturb glucose, so monitoring is reasonable in people with dysglycemia. In healthy men, 2 mg/day did not significantly affect fasting glucose (P=0.93) or insulin-stimulated glucose uptake (P=0.61) [4], and over the 52-week HIV program glucose changes were not clinically significant [2]. ## Does tesamorelin work for fat loss in non-HIV users? The pivotal efficacy trials were conducted in HIV-positive adults on antiretroviral therapy [1]. Generalizing to non-HIV populations is mechanistically plausible but not established by large RCTs [14]; a healthy-men study confirmed the GH/IGF-1 effect but measured hormones, not body-fat outcomes [4]. ## Is tesamorelin a potential treatment for non-alcoholic fatty liver disease? It has been studied as a research endpoint in HIV-associated fatty liver. A 6-month JAMA RCT reported a net hepatic-fat reduction of -2.9% [3], and a 2026 meta-analysis pooled a -4.28% hepatic-fat-fraction change [13]. These are research findings in HIV; treating NAFLD/MASLD is not an approved indication for tesamorelin [14]. ## How does tesamorelin affect the liver in NAFLD? In HIV patients, reduced visceral fat coincided with lower hepatic lipid; the 6-month JAMA trial reported a net hepatic-fat reduction of -2.9% (P=0.003) [3]. The benefit appears mediated by visceral-fat loss and GH/IGF-1 signaling rather than a direct hepatic drug effect [9]. ## Can tesamorelin reduce liver fat? In the studied HIV population, yes: a JAMA RCT measured a net hepatic-fat reduction of -2.9% [3], and a 2026 meta-analysis reported a hepatic-fat-fraction change of -4.28% [13]. This is research data in HIV-associated fatty liver, not an approved indication [14]. ## What is the half-life of tesamorelin? Plasma exposure is short. Population PK modeling estimated apparent clearance near 1,060 L/h [16]; secondary sources (the FDA label, Mayo Clinic) describe a terminal half-life on the order of 26 to 38 minutes. Despite rapid clearance, downstream IGF-1 elevation persists across the dosing interval, supporting once-daily use [16]. ## How long does tesamorelin stay in your system? The peptide itself clears rapidly from plasma (apparent clearance ~1,060 L/h), but its biological effect outlasts it: the IGF-1 rise it triggers persists across a once-daily dosing interval [16]. Population PK found the absorbed fraction roughly 13% higher by day 14 than day 1 [16]. ## What are the side effects of tesamorelin? Reported effects center on injection-site reactions and growth-hormone-class effects such as fluid retention, arthralgia, and modest glucose perturbation [15]. A 2026 sports-medicine review classed it among GH-axis secretagogues with uncertain safety profiles [15], and active malignancy is a labeled contraindication because the drug raises IGF-1 [4]. ## Does tesamorelin cause water retention? Fluid retention is a recognized growth-hormone-class effect because tesamorelin raises endogenous GH and IGF-1 [4]. It is generally described as mild in the trials, alongside arthralgia and injection-site reactions among the more commonly reported effects [15]. ## Who should not take tesamorelin / who should avoid it? Active malignancy is a labeled contraindication — the drug stimulates endogenous GH and raises serum IGF-1, a growth factor [4]. The literature also flags caution in individuals with prediabetes or dysglycemia given possible modest glucose perturbation [7], and notes generalizability beyond the studied HIV population is not established [14]. ## Does tesamorelin raise IGF-1 levels? Yes — raising IGF-1 is central to its mechanism. In the pivotal HIV trial IGF-1 rose 81% [1], and in healthy men it rose by 181 ug/L [4]. Because IGF-1 is a growth factor, GH-axis stimulation is why active malignancy is a labeled contraindication [4]. ## How does tesamorelin stimulate growth hormone release? It binds the Gs-coupled GHRH receptor on pituitary somatotrophs, raising intracellular cAMP and activating PKA, which drives GH gene transcription and granule exocytosis [4]. Its DPP-IV-resistant N-terminus lets it sustain this signaling longer than native GHRH, producing pulsatile GH secretion [8]. --- Tesamorelin read down to its numbers — one GHRH(1-44) analogue, the visceral-fat and IGF-1 figures left standing alone against the studies that measured them, and the approved-for-HIV-lipodystrophy line drawn exactly where the off-label field begins; an editorial reference plate, not a clinic, a vendor, or a prescription.